Back

Generation and validation of a mouse model of the phospholamban p.Arg14del mutation

27 May 2018 (14:15 - 14:30)
Organised by:
Congress Presentation Part of: Young Investigator Award: Basic Science and Translational Science Experimental Heart Failure HFA Premium Access Heart Failure 2018

About the speaker

Photo
Mr Tim Eijgenraam

University Medical Centre Groningen, Groningen (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
HDAC inhibitors repress cardiac hypertrophy through hyperacetylation of 14-3-3 chaperones and nuclear accumulation of class II HDACs
Mr D. Finke (Heidelberg, DE)
Abstract
Presentation thumbnail
Changes in titin phosphorylation and PKG activity underlie diastolic dysfunction at the cross-bridge level in the early stages of type 2 diabetes
Doctor M. Waddingham (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Myocyte BDNF generation prevents chronic post-ischemic decompensation via cardiac reinnervation: the role of beta-AR and GRK2 signals.
Doctor A. Cannavo (Napoly, IT)
Abstract Slides Video
Presentation thumbnail
Desmosomal integrity is challenged by exercise-induced strain in iPSC-derived cardiomyocytes with a novel desmoplakin mutation
Ms M. Vermeer (Groningen, NL)
Abstract
Presentation thumbnail
The myocardial infarction context dictates the phenotypic polarisation of antigen-specific CD4+T-cells and favours pro-healing responses in the wounded myocardium
Mr M. Rieckmann (Halle, DE)
Abstract

Access the full session

Session thumbnail
Young Investigator Award: Basic Science and Translational Science

The Event

Event poster

Heart Failure 2018

27 May 2018 14:15 CET
You may be interested in
thumbnail
Congress Session
Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments
thumbnail
Congress Presentation
From hypertension to heart failure: pathophysiology
thumbnail
Congress Session
From genetic signatures to clinical implications

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources